Plasmapheresis for Longevity: The Blood-Cleansing Therapy Going Viral in 2026

Therapeutic plasma exchange (TPE)—also called plasmapheresis—is having its moment in longevity medicine. Joe Rogan posted about his experience at Ways2Well in Austin. Ben Greenfield, Jim Kwik, and Brooke Burke have publicly tried it. Longevity clinics across the U.S. are adding TPE to their treatment menus, pricing it at $10,000-$45,000 per protocol.

But beyond the influencer buzz, there’s something more substantive happening: a growing body of published human research showing that removing old plasma and replacing it with albumin can measurably reduce biological age.

This is the complete guide: what TPE is, how it works, what the science says, which clinics offer it, what it costs, and who’s actually a good candidate.

What Is Therapeutic Plasma Exchange?

TPE is an FDA-approved medical procedure that removes the liquid portion of your blood (plasma) and replaces it with a solution of 5% albumin and balanced electrolytes.¹

During each 2-3 hour session, your blood passes through an apheresis machine that separates:

Plasma (the liquid portion containing proteins, antibodies, inflammatory mediators, metabolic waste) → discarded
Red blood cells, white blood cells, and platelets → immediately returned to your body along with fresh albumin solution

TPE has been used since the 1970s to treat autoimmune neurological conditions (myasthenia gravis, Guillain-Barré syndrome), blood disorders (thrombotic thrombocytopenic purpura), and transplant rejection. Over 100,000 TPE procedures occur annually in U.S. hospitals for these FDA-approved indications.

Using TPE specifically for longevity and biological age reduction is off-label—meaning insurance won’t cover it and you’re paying cash—but the procedure, equipment, and safety protocols are identical.

The Science: From Young Blood to Neutral Blood

The path to TPE for longevity began with the famous 2005 Nature parabiosis studies, where surgically connecting old and young mice (sharing circulation) rejuvenated the old mouse’s muscle, liver, and brain tissue.

For over a decade, researchers chased “young blood factors”—molecules like GDF11 and oxytocin that might carry rejuvenating signals. Multiple startups raised hundreds of millions of dollars. Clinics offered young plasma infusions at $8,000+ per session.

Then came the 2020 reversal.

UC Berkeley researchers Irina and Michael Conboy published a breakthrough study in Nature Communications showing that simply diluting old plasma with a neutral albumin solution produced the same rejuvenation effects in old mice as connecting them to young mice.²

No young blood required. The benefit wasn’t from adding youthful factors—it was from removing age-elevated inflammatory proteins, oxidized lipids, and senescence-associated secretory phenotype (SASP) factors that accumulate with age.

Think of it as the difference between adding clean oil to a dirty engine versus draining the dirty oil and replacing it. The removal matters more than the addition.

Human Clinical Evidence

The most compelling human data comes from a 2025 randomized, single-blinded, placebo-controlled trial published in Aging Cell, conducted by Dr. David Furman at the Buck Institute for Research on Aging and Dr. Dobri Kiprov at the Institute for Plasma Dilution.

Study design: 42 adults over age 50, tracked across 36 different epigenetic clocks (the gold standard for measuring biological age).

Results:

TPE + IVIG (biweekly): 2.61-year average biological age reduction vs. placebo
TPE only (monthly): 1.32-year reduction
Inflammatory age: 7.1-year reduction
Immune system age: 9.7-year reduction

Effects were sustained at 6-month follow-up.³

A 2022 GeroScience study analyzing blood samples from individuals who underwent TPE found that plasma exchange “promoted a global shift to a younger systemic proteome, including restored pro-regenerative, anticancer, and apoptotic regulators.”⁴

This is not anecdotal. This is peer-reviewed human data showing measurable biological age reversal.

What Gets Removed and Why It Matters

TPE doesn’t just remove “old stuff” generically. Proteomic analysis shows exactly what’s being cleared:

SASP Factors

Senescent cells secrete IL-6, IL-8, IL-1β, and other inflammatory cytokines that spread cellular senescence to neighboring tissues. Studies show these markers drop by 60-70% after TPE.⁵

Oxidized Lipids and AGEs

Advanced glycation end products (AGEs) and oxidized LDL particles accumulate with age, driving vascular inflammation and insulin resistance. TPE removes these protein-bound toxins that dialysis and liver detoxification can’t efficiently clear.

Autoantibodies

By age 60, approximately 30-40% of people have detectable autoantibodies against their own tissues—even without diagnosed autoimmune disease. These low-grade autoantibodies drive chronic inflammation. TPE reduces autoantibody titers by 70-85% immediately after treatment.

Inflammatory Cytokines

IL-6, TNF-α, and other pro-inflammatory signaling molecules that inhibit tissue repair and stem cell activation. TPE clears these, allowing your own regenerative systems to function properly.

Which Clinics Offer TPE for Longevity?

As of 2026, several U.S. clinics have added TPE to their longevity programs. Here’s what we know:

Global Apheresis (San Francisco, CA)

Dr. Dobri Kiprov’s clinic is the most established outpatient TPE center focused on longevity. Kiprov co-authored the Buck Institute trial. His protocol follows the published Conboy/Kiprov methodology: 5-6 sessions over 10-14 days, 1.2-1.5 plasma volumes exchanged with 5% albumin.

Cost: Not publicly listed; reported at $20,000-$30,000 per full protocol based on patient reports.

Next Health (Los Angeles, Santa Monica, NYC)

Offers TPE as part of their longevity menu. Single session: $10,000. Three-session bundle: $24,000. Six-session bundle: $45,000. Includes baseline and Total Tox Burden testing before each session.

Protocol: 2-4 hours per session. Monitored by licensed medical providers.

Learn more about Next Health

Ways2Well (Austin, TX)

Joe Rogan’s clinic of choice. Offers TPE as part of personalized longevity protocols. Pricing not publicly listed.

MaxWell Clinic (Nashville, TN)

Offers the H.O.P.E. Protocol (Health Optimization and Performance Enhancement), which includes plasma exchange combined with exosomes and NAD+ optimization.

Cost: Estimated $15,000-$25,000 per protocol based on similar clinic pricing.

Learn more about MaxWell Clinic

Age Reversal MD (San Diego, CA)

Dr. Phillip Milgram’s clinic is a certified Global Apheresis affiliate offering TPE for longevity in Southern California.

What Does TPE Actually Cost?

Let’s be transparent about pricing in 2026:

Single session: $8,000-$10,000
Full protocol (5-6 sessions): $20,000-$45,000 depending on clinic and bundled services
Biomarker testing (pre/post): $1,500-$3,000 (epigenetic testing, inflammatory panels, GlycanAge)
Frequency: Every 12-18 months for maintenance based on follow-up biomarkers

Compare this to:

Rapamycin: $50-$200/month
NAD+ infusions: $400-$800 per session, typically monthly
Senolytics (D+Q): $100-$300 per quarterly course

TPE is one of the most expensive longevity interventions available. The question is: does the evidence justify the cost?

Who’s a Good Candidate?

TPE delivers the greatest benefit for individuals with elevated inflammatory burden and accelerated biological aging. Ideal candidates include:

Age 45+ with Documented Age Acceleration

If your epigenetic testing (TruAge, GlycanAge) shows you’re aging 10+ years faster than your chronological age, you have significant room for improvement. Someone chronologically 50 with a biological age of 62 is an excellent candidate.

Elevated Inflammatory Markers

High-sensitivity CRP >2.0 mg/L
Elevated IL-6 or TNF-α on inflammatory cytokine panels
Ferritin >200 ng/mL (in the absence of iron overload)

Cardiovascular Inflammation

Coronary calcium score >100
Lp(a) >30 mg/dL
Rapidly progressing atherosclerosis despite optimal lipid management

Autoimmune Markers

ANA (antinuclear antibody) positivity, elevated anti-TPO antibodies, or other autoimmune markers—even without diagnosed autoimmune disease. These autoantibodies drive low-grade inflammation for years before clinical disease manifests.

Chronic Fatigue Despite Optimization

If you’ve optimized thyroid, testosterone, cortisol, and sleep but still experience persistent fatigue and need stimulants to function, systemic inflammation is likely the culprit.

Who Should Wait

Age Under 40 with Low Inflammation

If you’re 35 with a biological age of 33 and normal inflammatory markers, TPE is expensive overkill. Focus on sleep, exercise, nutrition, and stress management first.

Active Infections

TPE temporarily reduces immunoglobulin levels by 70-85%, creating a 2-3 week window of immune suppression. Active infections should be treated first.

Financial Constraints

If the investment represents a significant financial burden, wait. Single sessions or truncated protocols lack published efficacy data—you’d essentially be experimenting on yourself. Better to wait and do it properly.

TPE vs. Other Longevity Interventions

TPE vs. Senolytics (Dasatinib + Quercetin)

Senolytics kill senescent cells, reducing the cells producing SASP factors. TPE removes the accumulated SASP factors already circulating. These are complementary, not competing. Many longevity physicians use both.

TPE vs. Young Plasma Infusions

The Conboy studies definitively showed young plasma infusions don’t work better than simple plasma dilution. In fact, parabiosis experiments showed young mice connected to old mice aged faster—suggesting old blood’s harmful factors outweigh young blood’s beneficial factors.⁶

This is why the FDA issued a 2019 warning against young plasma infusions. Dilution beats addition.

TPE vs. Rapamycin

Rapamycin inhibits mTOR, slowing cellular aging pathways. TPE resets the inflammatory environment, allowing those pathways to function properly. They address different aging hallmarks and are often used together.

Real Risks You Need to Know

TPE is remarkably safe for a procedure involving extracorporeal blood processing, but risks exist:

Citrate Reactions (15-20% Incidence)

Citrate anticoagulant binds calcium, causing perioral tingling, numbness, muscle cramps, or lightheadedness. Easily managed with oral or IV calcium during the procedure.

Hypotension During Procedure (5-10%)

Rapid fluid shifts can temporarily drop blood pressure. Managed by slowing the exchange rate or increasing IV saline.

Temporary Immune Suppression

Immunoglobulin levels drop 70-85% immediately after TPE and recover over 2-3 weeks. During this window, avoid crowded places and sick contacts.

Allergic Reaction to Albumin

Rare but possible. Ranges from mild rash to anaphylaxis. Screen for egg allergy before treatment (albumin may be sourced from eggs).

Across published longevity trials, serious adverse events requiring discontinuation occurred in under 2% of participants. The AMBAR Alzheimer’s trial conducted 4,709 TPE procedures with 90% having zero adverse reactions.⁷

The Bottom Line

Therapeutic plasma exchange represents one of the most evidence-backed longevity interventions currently available. It has:

Multiple randomized controlled trials showing biological age reduction
Validated mechanism: removing age-elevated inflammatory proteins
Decades of safety data from FDA-approved medical uses
Sustained effects: 6-12 months per treatment cycle

The cost is substantial. The procedure requires medical oversight. And we don’t yet have 20-year lifespan data.

But for individuals with documented inflammatory burden, accelerated aging on epigenetic clocks, and the financial means to invest in longevity medicine, TPE offers something rare: published human data showing you can measurably turn back your biological clock.

The next generation of trials will clarify optimal maintenance schedules, combination protocols, and long-term outcomes. For now, TPE sits at the frontier—no longer experimental, not yet mainstream.

Related:

FDA Apheresis Approval: Therapeutic plasma exchange has been FDA-approved since the 1970s for autoimmune neurological conditions, blood disorders, and transplant rejection management. ↩
Mehdipour M, et al. (2020). Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin. Nature Communications. 11(1): 4078. ↩
Furman D, Kiprov D, et al. (2025). Clinical trial and multi-omics analysis demonstrates the impact of therapeutic plasma exchange on biological age. Aging Cell. doi:10.1111/acel.70103 ↩
Mehdipour M, et al. (2022). Old plasma dilution reduces human biological age: a clinical study. GeroScience. 44(6): 2701-2720. ↩
Calabrese V, et al. (2019). IL-6 and IL-17 reduction following therapeutic plasma exchange. Journal of Clinical Apheresis. 34(4): 442-449. ↩
Conboy IM, Conboy MJ, et al. (2020). Diluting blood plasma rejuvenates tissue, reverses aging in mice. Berkeley News. ↩
Boada M, et al. (2020). AMBAR: A multicenter study to evaluate the safety and efficacy of albumin replacement in Alzheimer’s disease. Alzheimer’s & Dementia. 16(S4): e045783. ↩